Eric H. Bjerkholt

2018 - Aimmune Therapeutics

In 2018, Eric H. Bjerkholt earned a total compensation of $2.1M as Chief Financial Officer at Aimmune Therapeutics, a 45% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$175,500
Option Awards$1,200,251
Salary$411,667
Stock Awards$319,406
Other$2,000
Total$2,108,824

Bjerkholt received $1.2M in option awards, accounting for 57% of the total pay in 2018.

Bjerkholt also received $175.5K in non-equity incentive plan, $411.7K in salary, $319.4K in stock awards and $2K in other compensation.

Rankings

In 2018, Eric H. Bjerkholt's compensation ranked 5,451st out of 14,244 executives tracked by ExecPay. In other words, Bjerkholt earned more than 61.7% of executives.

ClassificationRankingPercentile
All
5,451
out of 14,244
62nd
Division
Manufacturing
2,059
out of 5,759
64th
Major group
Chemicals And Allied Products
754
out of 2,122
65th
Industry group
Drugs
632
out of 1,811
65th
Industry
Pharmaceutical Preparations
486
out of 1,385
65th
Source: SEC filing on April 10, 2019.

Bjerkholt's colleagues

We found five more compensation records of executives who worked with Eric H. Bjerkholt at Aimmune Therapeutics in 2018.

2018

Jayson Dallas

Aimmune Therapeutics

Chief Executive Officer

2018

Douglas Sheehy

Aimmune Therapeutics

General Counsel

2018

Daniel Adelman

Aimmune Therapeutics

Chief Medical Officer

2018

Stephen Dilly

Aimmune Therapeutics

Chief Executive Officer

2018

Susan Barrowcliffe

Aimmune Therapeutics

General Manager, Europe

News

In-depth

You may also like